Skip to content
S4868Senate2021-2022 SessionSame asA333

Fund Lymphatic Disease Research

Official title

“Creates the lymphedema and lymphatic diseases research grants program and creates the lymphatic disease research and education fund”

Sponsor Timothy M. KennedySD-63Affects Finance
Status
Senate Floor Calendar
Impact
6/10
Moderate
Passage
0%

Bill progress

Vetoed via A333

What's happening

This bill creates a grants program and special fund to support research and education on lymphedema and lymphatic diseases in New York.

Why it matters

  1. Addresses funding gaps for underfunded research. By requiring applicants to demonstrate a lack of sufficient funding from other public or private sources, the grants program specifically targets lymphedema and lymphatic diseases research that may otherwise struggle to find financial support, potentially accelerating discoveries in neglected areas.

  2. Promotes collaboration and leverages private investment. The program gives priority to institutions that can secure private support or commit new resources, encouraging public-private partnerships and maximizing the impact of state funding.

  3. Supports transparency and long-term planning. The requirement for annual reporting—including summaries of all applicants, not just recipients—provides insight into the demand for funding, helps identify research trends or gaps, and builds a case for future appropriations.

  4. Protects proprietary research. By exempting confidential intellectual property from disclosure in reports, the bill balances transparency with the need to safeguard innovative work, which can help attract top-tier research institutions and commercial partnerships to New York.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Fund Lymphatic Disease Research

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Timothy M. Kennedy

Senator · Senate District 63

Chair, Transportation

No co-sponsors yet.

History

  1. Substituted by A333
  2. Ordered to third reading cal.1778
  3. Committee discharged and committed to rules
  4. Reported and committed to finance
  5. Referred to internet and technology

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A333Assembly

Fund Lymphatic Disease Research

Vetoed · Sponsor Linda Rosenthal

Impact 6 · ModerateVetoed

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

4868

2021-2022 Regular Sessions

IN SENATE

February 17, 2021

Introduced by Sen. KENNEDY -- read twice and ordered printed, and when printed to be committed to the Committee on Internet and Technology

AN ACT to amend the public authorities law, in relation to establishing a lymphedema and lymphatic diseases research grants program; and to amend the state finance law, in relation to creating the lymphedema and lymphatic diseases research and education fund

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The public authorities law is amended by adding a new section 3153-a to read as follows:

§ 3153-a. Lymphedema and lymphatic diseases research grants program. 1. The foundation shall, within available appropriations, establish the lymphedema and lymphatic diseases research grants program, hereafter "grants program." The grants program shall be administered by the foundation, in consultation with the department of health. Such grants program funds shall be used to provide financial assistance in the form of grants, not to exceed fifty thousand dollars per grant, to New York state biomedical research institutions for working capital to further new and emerging research and development for the diagnosis and treatment of lymphedema and lymphatic diseases. Such grants shall be awarded on a competitive basis to biomedical research institutions responding to requests for proposals issued by the foundation when funds are appropriated.

2. (a) "Biomedical research institution" shall mean a not-for-profit university, college, hospital, private or federal research laboratory located in New York state, or a consortium of such entities, that conducts an intensive and ongoing program of research and development directly related to lymphedema and/or lymphatic diseases research.

(b) "Lymphedema" shall mean an accumulation of lymphatic fluid in the interstitial tissue that causes swelling, most often in the arms and/or legs, and occasionally in other parts of the body, from any cause.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00469-01-1

S. 4868 2

(c) "Lymphatic diseases" shall include but not be limited to: insufficiency of lymphatic circulatory function (to include all forms of lymphedema), lipedema, complex congenital diseases of the lymphatic vasculature, including lymphangiomatosis, lymphangioleio-myomatosis, lymphangiectasias, lymphangiomas, cystic hygromas, Gorham's disease, lymphangiosarcoma, and complex vascular/lymphatic malformations.

3. In addition to such other criteria as the foundation may adopt in rules and regulations for the consideration of applications for grants pursuant to subdivision one of this section, the foundation shall:

(a) determine that the applicant is unable to obtain sufficient funding on reasonable terms from other public or private sources to permit the institution's planned investment to proceed without the required assistance;

(b) give priority to those applications for assistance from biomedical research institutions that secure private support for research or commit new resources to the expansion of lymphedema and lymphatic diseases research; and

(c) consider the potential long term economic benefits to the state of awarding the specific grant and whether the grant will result in a reasonable likelihood of success in meeting the purposes for which it was sought by the applicant.

4. The foundation, in consultation with the department of health, may apply to the national institutes of health, the United States department of health and human services, and other appropriate federal, public, and private entities for funding. Such monies shall be deposited into the lymphedema and lymphatic diseases research and education fund, established pursuant to section ninety-nine-ii of the state finance law.

5. The foundation shall submit to the governor, the speaker of the assembly, the temporary president of the senate, and to any other state legislator at his or her request, a report on the grants program by September first, two thousand twenty-three and annually thereafter. Such report shall include, for each grant awarded, the name and location of the recipient, a description of the product, device, technique, system or process being researched and developed, the recipient's relationship to the research institution, the amount and use of the grant, the total project cost, and such other information as the foundation shall deem appropriate. Such report shall also include a list of all applicants and their contact information, regardless of receiving a grant, in order to help demonstrate the need for future funds.

6. Nothing in this section shall require the foundation to disclose any matters involving confidential intellectual property or work product, whether patentable or not, including any formula, plan, pattern, process, tool, mechanism, compound, procedure, production data or compilation of information, which is not patented, but which is known only to certain individuals who are using it to fabricate, produce or compound an article of trade or service having commercial value and which gives its user an opportunity to obtain a business advantage over competitors who do not know it or use it.

§ 2. The state finance law is amended by adding a new section 99-ii to read as follows:

§ 99-ii. Lymphedema and lymphatic diseases research and education fund. 1. There is hereby established in the joint custody of the commissioner of taxation and finance and the comptroller, a special fund to be known as the lymphedema and lymphatic diseases research and education fund, hereafter the "fund".

S. 4868 3

2. Such fund shall consist of all monies appropriated, credited, or transferred thereto from any other fund or source pursuant to law. Nothing contained in this section shall prevent the state from receiving grants, gifts or bequests for the purposes of the fund as defined in this section and depositing them into the fund according to law.

3. Monies of the fund shall be expended only for lymphedema and lymphatic diseases research and education projects approved by the department of health.

4. (a) "Lymphedema" shall mean an accumulation of lymphatic fluid in the interstitial tissue that causes swelling, most often in the arms and/or legs, and occasionally in other parts of the body, regardless of cause.

(b) "Lymphatic diseases" shall include but not be limited to: insufficiency of lymphatic circulatory function (to include all forms of lymphedema), lipedema, complex congenital diseases of the lymphatic vasculature, including lymphangiomatosis, lymphangioleio-myomatosis, lymphangiectasias, lymphangiomas, cystic hygromas, Gorham's disease, lymphangiosarcoma, and complex vascular/lymphatic malformations.

(c) "Lymphedema and lymphatic diseases research and education projects" shall mean research by qualified researchers, as determined by the department of health, to stimulate research on the pathogenesis and new treatments for lymphedema and lymphatic diseases. Education projects are those projects which promote and provide information on lymphedema and lymphatic diseases including: prevention, diagnosis, treatment, long-term chronic care, and/or research by qualified organizations as determined by the department of health.

5. Monies shall be payable from the fund on the audit and warrant of the comptroller on vouchers approved and certified by the commissioner of health.

6. To the extent practicable, the commissioner of health shall ensure that all monies received during a fiscal year are expended prior to the end of that fiscal year.

§ 3. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public authorities law, in relation to establishing a lymphedema and lymphatic diseases research grants program; and to amend the state finance law, in relation to creating the lymphedema and lymphatic diseases research and education fund

Purpose

This bill establishes a lymphedema and lymphatic disease research grants program. Grants, not to exceed fifty thousand dollars, would be awarded on a competitive basis to biomedical research institutions that are conducting direct research related to lymphedema and lymphatic disease.

Summary of specific provisions

Section one amends the public authorities law by adding a new section 3153-A.

Section two amends state finance law by adding a new section 99-aa.

Section three sets forth the effective date.

Justification

This legislation would establish a lymphedema and lymphatic disease research grants program. Grants, not to exceed fifty thousand dollars, would be awarded on a competitive basis to biomedical research insti- tutions that are conducting direct research related to lymphedema and lymphatic disease.

Lymphedema is an accumulation of lymphatic fluid in the interstitial tissue that causes swelling, most often in the annex) or legs), and occasionally in other parts of the body. Lymphedema can develop when lymphatic vessels are missing" or impaired (primary), or when lymph vessels are damaged or lymph nodes removed (secondary). Radiation thera- py, used in the treatment of various cancers and some AIDS-related diseases, can damage otherwise healthy lymph nodes and vessels causing scar tissue to form which interrupts the normal flow of the lymphatic fluid.

Moreover, untreated, lymphedema can lead into a decrease or loss of, functioning of the Limbs, skin breakdown, and chronic infections. In the most severe cases, untreated lymphedema can develop into a rare form of lymphatic cancer. This legislation would provide much need funding to those involved in direct research of lymphedema or lymphatic diseases. These diseases are far more common than society notes; however, funding for research has historically not kept pace to the dramatically growing need for it.

Legislative history

2019-20: A.1021 - Reported to Ways and Means; S.4193 - Referred to Internet and Technology 2017-18: A.432 - Reported to Ways and Means; S.5063 - Committed to Rules 2015-16: A.230 - Vetoed; S.1058 - Vetoed 2013-14: A.8456 - Passed Assembly; S3072-A -Referred to Commerce, Economic Development and Small Business

Fiscal implications

Subject available to available appropriations.

Effective date

This bill shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.